Literature DB >> 16534678

The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Maximilian Schöniger-Hekele1, Christian Müller.   

Abstract

Increased tumor markers in patients with liver cirrhosis are often considered to be unspecific. The use of this unspecific elevation to discriminate minimal fibrosis from severe fibrosis has never been explored. We aimed to answer the question, Do tumor markers predict severe liver fibrosis? The study group consisted of 125 patients with alcoholic liver disease, hepatitis B, or hepatitis C with available liver biopsy. Tumor markers CA 19-9, CA 15-3, and CA 125 were determined using routine laboratory methods and correlated with the extent of liver fibrosis. Fibrosis stages 1 and 2 were classified as minimal fibrosis; stages 3 and 4, as severe fibrosis. Tumor markers CA 19-9, CA 125, and CA 15-3 increased with stage of fibrosis. For separating patients with mild fibrosis (F1+F2) from patients with severe fibrosis (F3+F4), CA 19-9 had a sensitivity of 70.5% and a specificity of 88.6, CA 125 had 38.1% and 89.7%, and CA 15-3 had 19.0% and 93.0%, respectively. Logistic regression of a combined score of CA19-9 and CA 125 values revealed that an increase of 1 point of the CA 19-9/CA125 score resulted in a 1.6 times increase in likelihood of the presence of severe fibrosis. The CA 19-9/CA 125 score achieved a similar specificity (97.1% vs. 100%) but a higher sensitivity (42.9% vs. 33.3%) than the widely used cirrhosis discriminant score of Bonacini. A specificity (98.5%) similar to that of the CA 19-9/CA 125 score was reached by the easier determination of the combined elevation of CA 19-9 and CA 125, which had the best positive predictive value, 92.9%. The excellent predictive ability of the combined elevation of CA 19-9 and CA 125 for severe liver fibrosis (F3+F4) was confirmed in an independent group of patients with liver disease. The combined elevation of CA 19-9 and CA 125 is useful for identifying patients with advanced fibrosis or cirrhosis with high specificity. Patients without a combined elevation of CA 19-9 and CA 125 still require histological examination to identify severe fibrosis or cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534678     DOI: 10.1007/s10620-006-3135-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

1.  Outpatient liver biopsy: how safe is it?

Authors:  G Garcia-Tsao; J L Boyer
Journal:  Ann Intern Med       Date:  1993-01-15       Impact factor: 25.391

2.  Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis.

Authors:  E Zuckerman; A Lanir; E Sabo; T Rosenvald-Zuckerman; I Matter; D Yeshurun; S Eldar
Journal:  Am J Gastroenterol       Date:  1999-06       Impact factor: 10.864

3.  Noninvasive diagnosis of hepatic fibrosis or cirrhosis.

Authors:  F Oberti; E Valsesia; C Pilette; M C Rousselet; P Bedossa; C Aubé; Y Gallois; H Rifflet; M Y Maïga; D Penneau-Fontbonne; P Calès
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

4.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.

Authors:  D V Mann; R Edwards; S Ho; W Y Lau; G Glazer
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

5.  Serum tumor markers in chronic liver disease.

Authors:  A Kadayifci; H Simsek; M C Savas; M Toppare
Journal:  Neoplasma       Date:  1996       Impact factor: 2.575

6.  Breast cancer-associated antigen CA 15.3 in liver cirrhosis.

Authors:  J Collazos; J Genolla; A Ruibal
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

7.  Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases.

Authors:  R Molina; X Filella; J Bruix; P Mengual; J Bosch; X Calvet; J Jo; A M Ballesta
Journal:  Clin Chem       Date:  1991-08       Impact factor: 8.327

8.  Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis.

Authors:  D Guyader; C Jacquelinet; R Moirand; B Turlin; M H Mendler; J Chaperon; V David; P Brissot; P Adams; Y Deugnier
Journal:  Gastroenterology       Date:  1998-10       Impact factor: 22.682

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

Authors:  P A Canney; M Moore; P M Wilkinson; R D James
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

View more
  11 in total

1.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

2.  Plasma miR-22-3p, miR-642b-3p and miR-885-5p as diagnostic biomarkers for pancreatic cancer.

Authors:  Neveen Abd El Moneim Hussein; Zenat A El Kholy; Medhat M Anwar; Mohamed A Ahmad; Shaymaa M Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-15       Impact factor: 4.553

3.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Authors:  Wei-Feng Shen; Wei Zhong; Feng Xu; Tong Kan; Li Geng; Feng Xie; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

4.  Rhizoctonia bataticola lectin induces apoptosis and inhibits metastasis in ovarian cancer cells by interacting with CA 125 antigen differentially expressed on ovarian cells.

Authors:  Prajna Hegde; Sindhura B R; Suhas Ballal; Bale M Swamy; Shashikala R Inamdar
Journal:  Glycoconj J       Date:  2021-11-08       Impact factor: 2.916

5.  Haemophagocytic lymphohistiocytosis presenting as liver failure following Epstein-Barr and prior hepatitis A infections.

Authors:  Gineth Paola Pinto-Patarroyo; Michael E Rytting; John Moore Vierling; Maria E Suarez-Almazor
Journal:  BMJ Case Rep       Date:  2013-08-13

6.  Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C.

Authors:  Mehdi Assmar; Sara Yeganeh; Fariborz Mansourghanaei; Nour Amirmozafari
Journal:  Iran J Public Health       Date:  2016-12       Impact factor: 1.429

7.  Mirrizi Syndrome and Markedly Elevated Levels of Carbohydrate Antigen 19-9 in the Absence of Malignant Disease.

Authors:  Natasha Shah; Eula Tetangco; Hafiz Muhammad Sharjeel Arshad; Hareth Raddawi
Journal:  Case Rep Gastrointest Med       Date:  2017-04-26

8.  The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis.

Authors:  Canturk Tascı; Sevket Ozkaya; Bikemgul Ozkara; Ergun Tozkoparan; Metin Ozkan; Nuri Karadurmus; Muhittin Serdar; Arzu Balkan; Hayati Bilgic
Journal:  Onco Targets Ther       Date:  2012-11-22       Impact factor: 4.147

9.  Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study.

Authors:  Mohamed A Alboraie; Mahmoud E Afifi; Fathy G Elghamry; Helmy A Shalaby; Gamal E Elshennawy; Ahmed A Abdelaziz; Mohamed U Shaheen; Amany R Abo El-Seoud
Journal:  Hepat Mon       Date:  2013-06-16       Impact factor: 0.660

10.  Carbohydrate 19.9 antigen serum levels in liver disease.

Authors:  Gaetano Bertino; Annalisa Maria Ardiri; Giuseppe Stefano Calvagno; Giulia Malaguarnera; Donatella Interlandi; Marco Vacante; Nicoletta Bertino; Francesco Lucca; Roberto Madeddu; Massimo Motta
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.